TrialResults-center.org

Menu

Nab-paclitaxel Taxanes
Description Results

Abraxane

Group by...

in first

in second

in third

All pathologies
advanced breast cancer (metastatic)

all type of patients 588 - 201

pdf

pathology

Benefit (demonstrated or suggested) and harm

advanced breast cancer (metastatic)

All results are NS for efficacy

Trial	control	p<0.05	harm	NS
Gradishar, 2009	vs docetaxel
Roy, 2008	vs docetaxel

Trial

Treatments

Patients

Method

Gradishar, 2009

weekly and every 3 week (q3w) nab-paclitaxel (n=302)

vs.

docetaxel (n=0)

first-line treatment in patients with MBC

Sample size: 302/0

Primary endpoint:

FU duration:

Roy, 2008

weekly nab (nanoparticle albumin-bound)-paclitaxel in combination with gemcitabine (n=50)

vs.

(n=0)

patients with previously untreated metastatic breast cancer

Sample size: 50/0

Primary endpoint:

FU duration:

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -